Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced completion of full enrollment for its Phase III clinical trial evaluating Anaprazole Sodium Enteric‑coated Tablets in Reflux Esophagitis (RE) – with all 500 subjects now randomized, positioning the innovative proton pump inhibitor (PPI) for potential label expansion beyond its June 2023 duodenal ulcer approval.
Clinical Milestone
Item
Detail
Company
Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575)
Product
Anaprazole Sodium Enteric‑coated Tablets
Trial Status
Phase III enrollment complete (n=500)
Indication
Reflux Esophagitis (RE) in adults
Prior Approval
June 2023 – Duodenal ulcer (NMPA)
Development Origin
Self‑developed by Xuanzhu
Product Profile – Innovative PPI Design
Feature
Anaprazole Sodium Mechanism
Clinical Advantage
Metabolic Pathway
Non‑enzymatic + multi‑enzymatic metabolism
Reduced dependency on single CYP pathway
CYP2C19 Involvement
Only 3.5% metabolized via CYP2C19
Genetic stability – efficacy unaffected by CYP2C19 polymorphisms (common with omeprazole, esomeprazole)
“Better suited for Chinese population” positioning
Market Impact & Outlook
PPI Market Dynamics: China PPI market RMB15‑20 billion annually; dominated by generic omeprazole/esomeprazole (60%+ share) and branded pantoprazole; innovation‑differentiated PPIs (dexlansoprazole, vonoprazan) capturing premium segment with 10‑15% annual growth.
Anaprazole Competitive Position: “Third‑generation” structural design (non‑enzymatic metabolism + dual excretion) distinguishes from CYP2C19‑dependent PPIs; genetic stability messaging resonates with Chinese market given CYP2C19 polymorphism prevalence; potential for hospital formulary preference in high‑risk populations.
Reflux Esophagitis Opportunity: GERD/RE affects >50 million Chinese adults; standard PPI therapy (8‑week healing) effective but relapse common; Anaprazole’s pharmacokinetic advantages may support faster healing or reduced relapse claims if Phase III data positive.
Clinical Timeline: Phase III completion (last patient last visit) expected H2 2026; NDA submission Q1‑Q2 2027; potential RE approval H2 2027‑H1 2028; label expansion supports RMB500‑800 million annual peak sales (2029‑2031) assuming NRDL inclusion.
Pipeline Synergies: Anaprazole platform validates Xuanzhu’s gastroenterology drug development capabilities; potential for combination products (PPI + H. pylori eradication regimens), pediatric formulations, or fixed‑dose combinations with prokinetics.
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase III data timelines, regulatory approval expectations, and commercial projections for Anaprazole Sodium in Reflux Esophagitis. Actual results may differ due to clinical trial outcomes, competitive dynamics with established PPIs, and reimbursement policy developments.-Fineline Info & Tech
By Fineline Cube 